Xilio Development Inc (XLO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $9.13 (+1.00%), Market cap $0.05B, 52-week low–high $0.51 ~ $8.81.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Financial statements, price targets, institutional (13F) holdings and related news for Xilio Development Inc are updated in real time on BlackAll Trade.
Xilio Development Inc trades at $9.13 (+1.00%). Real-time quotes and charts are available on BlackAll Trade.
Xilio Development Inc has a market cap of about $0.05B.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-